<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754494</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02984</org_study_id>
    <secondary_id>UCI06-8-01</secondary_id>
    <secondary_id>N01CN35160</secondary_id>
    <secondary_id>CDR0000614277</secondary_id>
    <nct_id>NCT00754494</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma</brief_title>
  <official_title>A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying how well erlotinib hydrochloride works in treating
      patients with stage I-III colorectal cancer or adenoma. Erlotinib hydrochloride may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking
      blood flow to the tumor. Erlotinib hydrochloride may also stop tumors from growing or coming
      back
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To test the hypothesis that erlotinib (erlotinib hydrochloride) doses as low as 25 mg will
      decrease aberrant crypt foci (ACF) phosphorylated extracellular signal-regulated kinases
      (pERK) levels from baseline (pre) to post erlotinib treatment.

      SECONDARY OBJECTIVES:

      I. To test the hypothesis that additional epidermal growth factor (EGF) inducible biomarkers
      will decrease from baseline (pre) to post treatment with erlotinib 25 mg, 50 mg or 100 mg
      orally (PO) once daily (QD) therapy.

      II. To determine the mean decrease from baseline of the ACF: normal mucosa pERK ratio pre and
      post 8-30 days of erlotinib.

      III. To determine erlotinib concentration in plasma and colorectal tissue at 25 mg, 50 mg and
      100 mg doses after 8-30 days of therapy.

      IV. To determine the incidence of rash, diarrhea and other side effects of low dose
      erlotinib.

      OUTLINE: Patients are randomized to 1 of 3 treatment arms.

      ARM I: Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.

      ARM II: Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.

      ARM III: Patients receive 25 mg of erlotinib hydrochloride PO and one 100 mg of placebo and
      one 25 mg of placebo PO QD.

      In all arms, treatment continues for 8-30 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up for 4 to 9 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ACF pERK Levels</measure>
    <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
    <description>Quantification will be performed by Western blot analysis. Tested using paired t-test with a two-sided significance level of 0.05.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EGF-inducible Markers - pEGFR in Normal Mucosa</measure>
    <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
    <description>pEGFR expression levels were quantified by immunoblotting and calculated as the ratio of the pEGFR signals to reference signals. A log-transformation of pEGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGF-inducible Markers - Total EGFR in Normal Mucosa</measure>
    <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
    <description>Total EGFR expression levels were quantified by immunoblotting and calculated as the ratio of the total EGFR signals to reference signals. A log-transformation of total EGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGF-inducible Markers - pEGFR in ACF</measure>
    <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
    <description>pEGFR expression levels were quantified by immunoblotting and calculated as the ratio of the pEGFR signals to reference signals. A log-transformation of pEGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGF-inducible Markers - Total EGFR in ACF</measure>
    <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
    <description>Total EGFR expression levels were quantified by immunoblotting and calculated as the ratio of the total EGFR signals to reference signals. A log-transformation of total EGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACF: Normal Mucosa pERK Ratio</measure>
    <time_frame>Up to day 30</time_frame>
    <description>Quantification will be performed by Western blot analysis. Tested using analysis of variance with subsequent pairwise comparisons using the Tukey method to adjust for multiple comparisons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Erlotinib Concentration (ng/mL)</measure>
    <time_frame>Up to day 30</time_frame>
    <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma OSI-420 Concentration (ng/mL)</measure>
    <time_frame>Up to day 30</time_frame>
    <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal Mucosa Erlotinib Concentration (ng/mg)</measure>
    <time_frame>Up to day 30</time_frame>
    <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal Mucosa OSI-420 Concentration (ng/mg)</measure>
    <time_frame>Up to day 30</time_frame>
    <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reported at Least 1 Side Effect During the Study</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Described for each arm using frequencies. The onset of adverse events is between randomization date and off-study date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reported at Least 1 Rash Side Effect During the Study</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Described for each arm using frequencies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Described for each arm using frequencies.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Adenomatous Polyp</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage I Colon Cancer</condition>
  <condition>Stage I Rectal Cancer</condition>
  <condition>Stage IIA Colon Cancer</condition>
  <condition>Stage IIA Rectal Cancer</condition>
  <condition>Stage IIB Colon Cancer</condition>
  <condition>Stage IIB Rectal Cancer</condition>
  <condition>Stage IIC Colon Cancer</condition>
  <condition>Stage IIC Rectal Cancer</condition>
  <condition>Stage IIIA Colon Cancer</condition>
  <condition>Stage IIIA Rectal Cancer</condition>
  <condition>Stage IIIB Colon Cancer</condition>
  <condition>Stage IIIB Rectal Cancer</condition>
  <condition>Stage IIIC Colon Cancer</condition>
  <condition>Stage IIIC Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib Hydrochloride (25 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib Hydrochloride (50 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib Hydrochloride (100 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Erlotinib Hydrochloride (25 mg)</arm_group_label>
    <arm_group_label>Erlotinib Hydrochloride (50 mg)</arm_group_label>
    <arm_group_label>Erlotinib Hydrochloride (100 mg)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Erlotinib Hydrochloride (25 mg)</arm_group_label>
    <arm_group_label>Erlotinib Hydrochloride (50 mg)</arm_group_label>
    <arm_group_label>Erlotinib Hydrochloride (100 mg)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Erlotinib Hydrochloride (25 mg)</arm_group_label>
    <arm_group_label>Erlotinib Hydrochloride (50 mg)</arm_group_label>
    <arm_group_label>Erlotinib Hydrochloride (100 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with one or more of the following criteria will be eligible to
             participate:

               -  History of Stage I-III colorectal cancer, not treated in the past 6 months with
                  no anticipated treatment in the next 3 months

               -  Adenoma ≥ 1 cm in size

               -  3 or more adenomas (of any size) removed at one colonoscopy within past 6 years

               -  Sessile serrated adenoma ≥ 5 mm in size

               -  Adenoma (of any size) with villous features (villous, tubulovillous)

               -  Adenoma (of any size) with high grade dysplasia

          -  Participants are eligible for randomization into the treatment phase of the trial if
             they are found to have ≥ 4 ACFs at either baseline colonoscopy or baseline flexible
             sigmoidoscopy

          -  Blood tests at screening which meet the following criteria:

          -  WBC &gt; 3000/mm^3

          -  Platelets &gt; 100,000/mm^3

          -  Hemoglobin &gt; 10g/dl

          -  Plasma creatinine of &lt; 1.6mg/dl

          -  Total bilirubin &lt; 1.5 x the upper limit of normal

          -  Serum ALT &lt; 1.5 x the upper limit of normal

          -  Serum AST &lt; 1.5 x the upper limit of normal

          -  ECOG performance status 0-1

          -  Women of child-bearing potential and men taking study drug must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation

          -  Ability to understand, as well as sign the written informed consent document

          -  If a woman is of child-bearing potential, she must have a negative pregnancy test
             prior to study entry; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her study physician immediately

        Exclusion Criteria:

          -  History of Inflammatory Bowel Disease (IBD)

          -  History of interstitial lung disease or chronic lung disease

          -  Smoking within the past 3 months

          -  Increased bleeding risk from rectal biopsy (Patients receiving aspirin or plavix can
             be enrolled)

          -  Patients receiving warfarin or coumadin

          -  Uncontrollable diarrhea of any cause

          -  Patients, including rectal cancer patients, that have received prior radiation to the
             rectum or pelvis

          -  Participants taking a known significant CYP 3A4 inducer or inhibitor; known
             significant inducers/inhibitors include: amprenavir, aprepitant, atazanavir,
             carbamazepine, clarithromycin, conivaptan, diltiazem, darunavir/ritonavir,
             dronedarone, erythromycin, fluconazole, fosamprenavir, indinavir, itraconazole,
             ketoconazole, nefazodone, nelfinavir, phenytoin, posaconazole, rifampin, ritonavir,
             St. John's wort, saquinavir, telithromycin, tipranavir/ritonavir, verapamil,
             voriconazole

          -  Women who are pregnant or breast-feeding

          -  Active keratoconjunctivitis, or corneal surgery in the past three weeks

          -  Any medical or psychosocial condition that could jeopardize the subject's
             participation in and compliance to the study

          -  Participants who are taking any other investigational pharmaceutical agents

          -  Previous history of sensitivity to erlotinib, Iressa, or Erbitux, such as a rash that
             is uncontrollable by topical steroids and/or antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Morgan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <results_first_submitted>April 23, 2014</results_first_submitted>
  <results_first_submitted_qc>December 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2015</results_first_posted>
  <last_update_submitted>December 22, 2014</last_update_submitted>
  <last_update_submitted_qc>December 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (25 mg)</title>
          <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (50 mg)</title>
          <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P3">
          <title>Arm III (100 mg)</title>
          <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (25 mg)</title>
          <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (50 mg)</title>
          <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Arm III (100 mg)</title>
          <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.67" spread="4.43"/>
                    <measurement group_id="B2" value="62.47" spread="6.03"/>
                    <measurement group_id="B3" value="60.67" spread="7.42"/>
                    <measurement group_id="B4" value="62.27" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in ACF pERK Levels</title>
        <description>Quantification will be performed by Western blot analysis. Tested using paired t-test with a two-sided significance level of 0.05.</description>
        <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
        <population>Change in ACF pERK levels not reported as the assay did not demonstrate signaling</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ACF pERK Levels</title>
          <description>Quantification will be performed by Western blot analysis. Tested using paired t-test with a two-sided significance level of 0.05.</description>
          <population>Change in ACF pERK levels not reported as the assay did not demonstrate signaling</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EGF-inducible Markers - pEGFR in Normal Mucosa</title>
        <description>pEGFR expression levels were quantified by immunoblotting and calculated as the ratio of the pEGFR signals to reference signals. A log-transformation of pEGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
        <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
        <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EGF-inducible Markers - pEGFR in Normal Mucosa</title>
          <description>pEGFR expression levels were quantified by immunoblotting and calculated as the ratio of the pEGFR signals to reference signals. A log-transformation of pEGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
          <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
          <units>expression level</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="0.27" upper_limit="2.58"/>
                    <measurement group_id="O2" value="1.65" lower_limit="0.87" upper_limit="3.10"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.68" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of pEGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.762</p_value>
            <method>General Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of pEGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <method>General Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of pEGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.855</p_value>
            <method>General Linear Model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EGF-inducible Markers - Total EGFR in Normal Mucosa</title>
        <description>Total EGFR expression levels were quantified by immunoblotting and calculated as the ratio of the total EGFR signals to reference signals. A log-transformation of total EGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
        <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
        <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EGF-inducible Markers - Total EGFR in Normal Mucosa</title>
          <description>Total EGFR expression levels were quantified by immunoblotting and calculated as the ratio of the total EGFR signals to reference signals. A log-transformation of total EGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
          <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
          <units>expression level</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="0.44" upper_limit="9.40"/>
                    <measurement group_id="O2" value="1.91" lower_limit="0.91" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.23" lower_limit="0.88" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of total EGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.369</p_value>
            <method>General Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of total EGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>General Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of total EGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>General Linear Model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EGF-inducible Markers - pEGFR in ACF</title>
        <description>pEGFR expression levels were quantified by immunoblotting and calculated as the ratio of the pEGFR signals to reference signals. A log-transformation of pEGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
        <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
        <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EGF-inducible Markers - pEGFR in ACF</title>
          <description>pEGFR expression levels were quantified by immunoblotting and calculated as the ratio of the pEGFR signals to reference signals. A log-transformation of pEGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
          <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
          <units>expression level</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.57" upper_limit="2.48"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.07" upper_limit="3.48"/>
                    <measurement group_id="O3" value="1.40" lower_limit="0.78" upper_limit="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of pEGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.651</p_value>
            <method>General Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of pEGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>General Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of pEGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median pEGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.261</p_value>
            <method>General Linear Model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EGF-inducible Markers - Total EGFR in ACF</title>
        <description>Total EGFR expression levels were quantified by immunoblotting and calculated as the ratio of the total EGFR signals to reference signals. A log-transformation of total EGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
        <time_frame>From baseline to post-treatment (up to 30 days)</time_frame>
        <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EGF-inducible Markers - Total EGFR in ACF</title>
          <description>Total EGFR expression levels were quantified by immunoblotting and calculated as the ratio of the total EGFR signals to reference signals. A log-transformation of total EGFR was utilized in primary analyses. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</description>
          <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
          <units>expression level</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="0.38" upper_limit="4.61"/>
                    <measurement group_id="O2" value="2.22" lower_limit="1.08" upper_limit="4.54"/>
                    <measurement group_id="O3" value="1.94" lower_limit="0.92" upper_limit="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of total EGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.654</p_value>
            <method>General Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of total EGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>General Linear Model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A log-transformation of total EGFR was utilized in primary analyses because of the highly skewed distribution observed in this outcome. The general linear model was used to estimate and compare the relative change in median total EGFR with adjustment for actin as a normalizing factor. The estimated relative change (post:pre) in the median, corresponding 95% confidence interval, and p-value for testing the null hypothesis of equal medians comparing pre- and post-measurements were reported.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>General Linear Model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACF: Normal Mucosa pERK Ratio</title>
        <description>Quantification will be performed by Western blot analysis. Tested using analysis of variance with subsequent pairwise comparisons using the Tukey method to adjust for multiple comparisons.</description>
        <time_frame>Up to day 30</time_frame>
        <population>ACF: pERK ratio not reported as the assay did not demonstrate signaling in ACF pERK levels</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>ACF: Normal Mucosa pERK Ratio</title>
          <description>Quantification will be performed by Western blot analysis. Tested using analysis of variance with subsequent pairwise comparisons using the Tukey method to adjust for multiple comparisons.</description>
          <population>ACF: pERK ratio not reported as the assay did not demonstrate signaling in ACF pERK levels</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Erlotinib Concentration (ng/mL)</title>
        <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
        <time_frame>Up to day 30</time_frame>
        <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Erlotinib Concentration (ng/mL)</title>
          <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
          <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.29" spread="160.6"/>
                    <measurement group_id="O2" value="486.56" spread="211.8"/>
                    <measurement group_id="O3" value="1280.84" spread="788.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma OSI-420 Concentration (ng/mL)</title>
        <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
        <time_frame>Up to day 30</time_frame>
        <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma OSI-420 Concentration (ng/mL)</title>
          <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
          <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.77" spread="12.3"/>
                    <measurement group_id="O2" value="33.87" spread="14.1"/>
                    <measurement group_id="O3" value="117.98" spread="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normal Mucosa Erlotinib Concentration (ng/mg)</title>
        <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
        <time_frame>Up to day 30</time_frame>
        <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Normal Mucosa Erlotinib Concentration (ng/mg)</title>
          <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
          <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
          <units>ng/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.18"/>
                    <measurement group_id="O2" value="1.38" spread="1.23"/>
                    <measurement group_id="O3" value="3.25" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Normal Mucosa OSI-420 Concentration (ng/mg)</title>
        <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
        <time_frame>Up to day 30</time_frame>
        <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Normal Mucosa OSI-420 Concentration (ng/mg)</title>
          <description>Will be quantified in biopsy samples using appropriate descriptive statistics (means and standard deviations).</description>
          <population>Outcome measure data is reported based on the evaluable samples collected and available results.</population>
          <units>ng/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.01"/>
                    <measurement group_id="O2" value="0.17" spread="0.15"/>
                    <measurement group_id="O3" value="0.29" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reported at Least 1 Side Effect During the Study</title>
        <description>Described for each arm using frequencies. The onset of adverse events is between randomization date and off-study date.</description>
        <time_frame>Up to 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reported at Least 1 Side Effect During the Study</title>
          <description>Described for each arm using frequencies. The onset of adverse events is between randomization date and off-study date.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 adverse event reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No adverse event reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reported at Least 1 Rash Side Effect During the Study</title>
        <description>Described for each arm using frequencies.</description>
        <time_frame>Up to 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reported at Least 1 Rash Side Effect During the Study</title>
          <description>Described for each arm using frequencies.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 rash AE reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No rash AE reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study</title>
        <description>Described for each arm using frequencies.</description>
        <time_frame>Up to 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (25 mg)</title>
            <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 10 to 29 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II (50 mg)</title>
            <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 8 to 28 days</description>
          </group>
          <group group_id="O3">
            <title>Arm III (100 mg)</title>
            <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies
The range of days on treatment is 7 to 23 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study</title>
          <description>Described for each arm using frequencies.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 diarrhea AE reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No diarrhea AE reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The onset date of adverse event is between the randomization date and the date of off-study, up to 95 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (25 mg)</title>
          <description>Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (50 mg)</title>
          <description>Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E3">
          <title>Arm III (100 mg)</title>
          <description>Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
erlotinib hydrochloride: Given PO
placebo: Given PO
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EARACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLURRING OF VISION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY EYES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY ITCHY EYE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRYNESS OF EYES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>ITCHINESS OF EYES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RED PUFFY EYES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>SEEING BLACK SPOTS AND FLASHING LIGHTS IN LEFT EYE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DIARRHEA-FREQUENT BM'S</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>HEARTBURN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>INCARCERATED HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>LOOSE STOOLS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>LOSS OF APPETITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>LOTS OF GAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>MILD DIARRHEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>MILD INDIGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>PAIN ON ABDOMEN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>VOMIT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>COLD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>FLU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP BRUISED LFT LEG PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DULL SORENESS IN LEG</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>PAIN ON FOOT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>SHOULDER PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>SWOLLEN LEFT KNEE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>LIGHT HEADED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>IRRITABLE-MOOD ALTERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLUE COLORED URINE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>BLUE/GREEN COLORED URINE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BLOODY NOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>NOSE BLEED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RUNNY NOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>SHORT OF BREATH EASILY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>SHORT OF BREATH-DYSPNEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>80% DIMINISHED SEBORRHEIC KERATOSIS SKIN LESIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>ALLERGIC REACTION: RASH ON THE FACE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CANKER SORES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>CLEARED UP ACNE ON MY FOREHEAD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY &amp; ITCHY SKIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY SKIN AROUND NOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY SKIN ON NOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRY SKIN-(LEGS)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>DRYNESS OF SKIN ON FACE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>FACE PIMPLES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>FACE SORE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>FOLLICULAR RASH ON TORSO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>MILD RASH IN THE BUTTOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>MOUTH SORES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>PAINFUL ITCHY &amp; TENDER SCALP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH ON CHEST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH ON FACE, CHEST AND SHOULDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH ON FACE, CHEST, AND BEHIND EARS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH ON FACE, SCALP AND CHEST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH ON FACE, SCALP, CHEST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH ON FACE, SCALP, CHEST, BACK, EXTREMITIES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH ON FOOT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RASH ON FOREHEAD/NOSE/CHEST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RAW NOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RED ITCHY FACE RASH ON CHEEKS &amp; NOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RED RASH-FACE PEELING &amp; NOW WHITE HEAD PIMPLES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RED RASH-FACE,NOSE, &amp; CHEST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RED RASH-FACE-NECK-CHEST &amp; SCALP-ITCHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>RED,BUMPY FACE &amp; CHEST RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>SWOLLEN FACE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>ULCER ON MUCOUS MEMBRANE IN MOUTH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Timothy R. Morgan</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>562-826-5756</phone>
      <email>timothy.morgan@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

